Tissue Regenix Group (TRX)
TRX Share PerformanceMore
|52 week high||21.000 03/01/17|
|52 week low||7.800 27/10/17|
|52 week change||-7.125 (-46.34%)|
|4 week volume||32,575,187 24/10/17|
Latest News« previous» nextMore
02/11/2017 - 09:06 StockMarketWire
Tissue Regenix, a regenerative medical devices company, has appointed Steve Couldwell as chief executive officer of the gr...
02/11/2017 - 07:00 RNS
RNS Number: 3338V Tissue Regenix Group PLC 02 November 2017 Tissue Regenix Group plc Appointment of CEO Steve Couldwell appointed Group CEO Leeds, 02 November 2017 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company announces the appointment of Steve Couldwell, as Chief Executive Off...
18/10/2017 - 06:00 RNS
RNS Number: 8786T Tissue Regenix Group PLC 18 October 2017 [This announcement contains inside information.] Tissue Regenix Group plc Directorate Change Leeds, 18 October 2017 - The Board of Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix" or "The Group") today announces that Antony Odell, Chief Executive Officer (CEO), will be stepping down fro...
11/10/2017 - 06:15 RNS
RNS Number: 2491T Tissue Regenix Group PLC 11 October 2017 Hardman Research: Dual revenue stream growth Dual revenue stream growth - TRX has a broad portfolio of regenerative medicine products developed from decellularised human and porcine soft tissues for the wound care, orthopaedics, and cardiac markets. Since the launch of DermaPure, focus has...
28/09/2017 - 14:15 RNS
RNS Number: 1381S Tissue Regenix Group PLC 28 September 2017 Tissue Regenix Group plc Unaudited Interim Results for the six months ended 30 June 2017 Leeds, 28 th September 2017 - Tissue Regenix Group (AIM:TRX) "Tissue Regenix" or "The Group", the regenerative medical devices company, today announces its unaudited interim results for the six months en...
18/09/2017 - 13:41 Interactive Investor
After a busy summer for Neil Woodford, David Brenchley reveals what the star fund manager bought and sold last mon...
08/09/2017 - 06:00 RNS
RNS Number: 2015Q Tissue Regenix Group PLC 08 September 2017 Tissue Regenix Group plc Notice of Interim Results and Capital Markets Day Leeds, 8 September 2017 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company, today gives notice that it will announce its interim results for the six months ending...
05/09/2017 - 14:52 RNS
RNS Number: 8912P Tissue Regenix Group PLC 05 September 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Tissue R...
|Dividend yield||0 %|
Latest discussion posts More
“No response to my email enquiry. Shareholder comms v.poor. But, now we have a new CEO. Been on the board as non exec director since 2013 so he knows how it works. Let?s hope ...”▼
“Worryingly and surprisingly the sp has continued to slip. Something needs to change. Board problems, product problems ? Without some clarification from those on high this ...”▼
“Well its never positive to not have mutually agreed and beneficial outcomes (and statement) as a shareholder you want to think the company has some integrity.More importantly ...”▼
Codes & Symbols
|Symbols||TRX, LSE:TRX, TRX.L, TRX:LN, LON:TRX, XLON:TRX|
Join interactive investor
- £22.50 fixed quarterly charge includes £22.50 in trading credits
- £10 per trade or £6 for frequent traders
- No % platform fees
- £1 per trade for regular investment or dividend reinvestment